- Home
- ROIV vs BG Comparison
ROIV vs BG Comparison
Compare ROIV & BG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | BG |
|---|---|---|
| Founded | 2014 | 1818 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Packaged Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.7B | 24.9B |
| IPO Year | 2021 | 2023 |
Fundamental Metrics
Financial Performance| Metric | ROIV | BG |
|---|---|---|
| Price | $28.62 | $124.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $27.56 | ★ $132.29 |
| AVG Volume (30 Days) | ★ 4.2M | 1.5M |
| Earning Date | 05-28-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 2.26% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 4.91 |
| Revenue | $29,053,000.00 | ★ $70,329,000,000.00 |
| Revenue This Year | N/A | $36.19 |
| Revenue Next Year | $878.32 | $3.15 |
| P/E Ratio | ★ N/A | $25.25 |
| Revenue Growth | N/A | ★ 32.43 |
| 52 Week Low | $9.90 | $71.60 |
| 52 Week High | $30.33 | $131.93 |
Technical Indicators
Market Signals| Indicator | ROIV | BG |
|---|---|---|
| Relative Strength Index (RSI) | 57.34 | 51.11 |
| Support Level | $26.45 | $111.01 |
| Resistance Level | $30.33 | $126.62 |
| Average True Range (ATR) | 0.96 | 4.16 |
| MACD | 0.05 | -0.59 |
| Stochastic Oscillator | 81.94 | 36.73 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About BG Bunge Limited
Bunge Global SA is an agribusiness solutions company, connecting farmers to consumers and delivering essential food, feed and fuel to the globe. The company segments include Soybean Processing and Refining; Softseed Processing and Refining; Other Oilseeds Processing and Refining; Grain Merchandising and Milling; and Corporate and Other. It generates maximum revenue from the Soybean Processing and Refining segment, which includes integrated business principally involved in the purchase, storage, transportation, processing, distribution, refining, marketing, and sale of soybeans and soybean related products, as well as biodiesel and fertilizer production and distribution. Geographically, the company operates in United States, Switzerland, Netherlands, and Rest of the World.